Report
EUR 13.18 For Business Accounts Only

Thanks to a better fundamental star rating, NOVAVAX sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to NOVAVAX (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date November 19, 2021, the closing price was USD 192.34 and its expected value was estimated at USD 181.50.
Underlying
Novavax Inc.

Novavax is a late-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. The company's vaccine candidates, including its primary candidates, ResVax? and NanoFlu?, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. The company's product pipeline targets a variety of infectious diseases. The company is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company's primary adjuvant, Matrix-M?, has been shown to improve immune responses and was well-tolerated in multiple clinical trials.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch